Company profile for Longbio Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

LongBio Pharma is a biotech company based in Shanghai, China, established in 2018. The company has a focus on autoimmune and rare diseases with a commitment to serving patients and society. Dr. Sun, Bill, Nai-chau, co-founder of LongBio Pharma, has a notable background as the co-founder of Tanox, which went public on Nasdaq in 2000 and was later acquired by Genentech in 2007. He is also the co-inventor of Omalizumab (Xolair®)...
LongBio Pharma is a biotech company based in Shanghai, China, established in 2018. The company has a focus on autoimmune and rare diseases with a commitment to serving patients and society. Dr. Sun, Bill, Nai-chau, co-founder of LongBio Pharma, has a notable background as the co-founder of Tanox, which went public on Nasdaq in 2000 and was later acquired by Genentech in 2007. He is also the co-inventor of Omalizumab (Xolair®), the first anti-IgE antibody approved by the FDA, with global sales reaching 3.6 billion USD in 2022. LongBio Pharma aims to introduce its drugs to both domestic and international markets through partnerships.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Dongnan Avenue, Changshu, Jiangsu
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/breakthrough-exciting-interim-phase-ii-data-of-lp-003-in-csu-released-by-longbio-at-aaaai-2025-302389413.html

PR NEWSWIRE
03 Mar 2025

https://www.prnewswire.com/news-releases/food-allergy-longbios-lp-003-achieves-its-fourth-ind-approval-302315417.html

PR NEWSWIRE
25 Nov 2024

https://www.prnewswire.com/news-releases/longbio-announced-the-completion-of-series-b2-financing-led-by-qiming-venture-partners-302256825.html

PR NEWSWIRE
24 Sep 2024

https://www.prnewswire.com/news-releases/pre-clinical-result-of-lp-005-a-novel-bi-functional-complement-antibody-fusion-protein-was-unveiled-by-longbio-at-wcn2024-302116666.html

PR NEWSWIRE
15 Apr 2024

https://www.prnewswire.com/news-releases/longbio-pharma-presented-positive-phase-1-results-for-lp-003-at-2024aad-302085804.html

PR NEWSWIRE
12 Mar 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty